1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Anuh Pharma Limited

Anuh Pharma Limited

76.63
INR
-2.24
(-2.84%)
4.41EPS
18.42P/E
8.14BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
26.58
28.31
32.55
20.57
23.76
31.99
30.63
43.1
48.56
52.63
64.56
66
76.99
77.78
Basic EPS, GAAP
1.76
2.19
2.57
2
1.65
2.33
1.43
2.84
3.05
3.61
5.99
4.72
4.1
4.41
Free Cash Flow per Basic Share
1.36
1.8
0.55
2.49
-0.5
-2.18
1.33
-2.48
2.72
5.22
0.79
1.69
-1.09
- -
Dividend per Share
0.71
0.82
1.1
0.15
0.75
0.83
1.66
- -
0.75
0.87
1
1.25
1.49
- -
Book Value per Share
8.57
10.07
12.18
14.02
14.93
16.42
16.18
19.02
21.33
24.07
29.06
32.53
35.14
- -
Tangible Book Value per Share
8.56
10.06
12.14
13.99
14.89
16.39
16.16
19
21.31
24.06
29.04
32.52
35.09
- -
Basic Weighted Avg Shares
100
100
100
100
100
100
100
100
100
100
100
100
100
100
Sales/Revenue/Turnover
2,664
2,837
3,262
2,061
2,381
3,207
3,070
4,320
4,866
5,275
6,470
6,615
7,717
7,790
Operating Margin (%)
9.81
10.78
11.61
10.09
8.56
10.27
7.67
7.05
7.65
8.43
10.46
8.59
7.38
6.87
Depreciation Expense
17
33
23
20
18
17
70
151
120
97
86
87
114
113
Net Income, GAAP
176
220
258
201
165
234
143
284
306
362
601
474
410
442
Effective Tax Rate (%)
30.96
30.98
31.98
27.32
29.49
27.89
25.32
26.24
21.88
23.78
23.31
22.38
24.3
26.62
Profit Margin (%)
6.6
7.75
7.91
9.73
6.94
7.29
4.66
6.58
6.28
6.86
9.28
7.16
5.32
5.67
Working Capital
647
767
801
905
955
774
602
983
1,278
1,463
1,858
1,977
2,483
- -
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
9
8
4
1
- -
- -
Total Equity
859
1,009
1,221
1,406
1,496
1,646
1,622
1,906
2,138
2,412
2,912
3,260
3,522
- -
Return on Invested Capital (%)
20.43
20.31
20.56
10.81
9.16
14.73
9.34
10.77
13.78
14.71
19.27
13.65
12.46
- -
Return on Capital (%)
21.76
23.57
22.94
15.17
11.31
14.63
7.92
14.35
14.83
15.8
22.51
15.17
12.02
- -
Return on Common Equity (%)
21.78
23.55
23.14
15.27
11.38
14.87
8.75
16.12
15.11
15.9
22.56
15.34
12.1
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
100
Market Capitalization
8,070
6,715
8,141

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
4,513
- -
Cash, Cash Equivalents & STI
- -
529
- -
Accounts Receivable, Net
- -
2,386
- -
Inventories
- -
1,478
- -
Total Current Liabilities
- -
2,030
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.33%
13.14%
8.04%
Free Cash Flow
-13.56%
-50.33%
-164.08%
Net Income, GAAP
11.89%
11.47%
-13.32%
Sales/Revenue/Turnover
11.24%
12.52%
16.65%
Total Cash Common Dividend
- -
- -
19.54%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,379
1,660
1,595
1,981
6,615
2026
1,865
1,859
1,972
2,021
7,717
2027
1,938
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.95
1.5
1.03
1.24
4.72
2026
0.83
0.76
1.34
1.17
4.1
2027
1.14
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.25
2026
- -
- -
- -
- -
1.49
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ritesh Bipin Shah
Full Time Employees
323
Sector
Health technology
Industry
Pharmaceuticals: major
Address
3-A, Shivsagar Estate Mumbai MA India 400018
IPO Date
Apr 19, 1995
Website
anuhpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Anuh Pharma Ltd. (ANUHPHR.NS) manufactures and markets active pharmaceutical ingredients (APIs), including oncology drugs, cardiovascular medications, anti-diabetic agents, anti-allergic products, and intermediates; it also produces advanced pharmaceutical intermediates and formulations for the global healthcare sector. The company operates primarily from its headquarters in Mumbai, India, where it was founded in 1960, with manufacturing facilities in Ambernath and additional operations focused on exports to regulated markets in the United States, Europe, and Asia. Its product portfolio encompasses key APIs such as paracetamol, ranitidine hydrochloride, cetirizine, metformin, and atenolol, alongside custom synthesis services for pharmaceutical intermediates targeting multinational pharmaceutical companies. Anuh Pharma maintains a strong emphasis on regulatory compliance, holding approvals from USFDA, EDQM, and WHO-GMP standards to serve diverse customer segments including generic drug manufacturers and contract development organizations. In recent developments, the company expanded its production capacity through investments in new API lines at its Ambernath facility in 2024, enhancing output for high-demand oncology and cardiovascular products; it also secured a strategic export partnership with a major US-based generic firm in early 2025, boosting its North American market presence amid growing global API demand.